

What is claimed is:

1. Use of an anti-C1q antibody or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of an inherited retinal disease in a human patient, wherein the medicament is for intravitreal injection at a dose of about 1 mg to about 10 mg of the anti-C1q antibody or an antigen-binding fragment thereof, and
wherein the anti-C1q antibody or an antigen-binding fragment thereof comprises a light chain variable domain comprising an HVR-L1 having the amino acid sequence of SEQ ID NO: 5, an HVR-L2 having the amino acid of SEQ ID NO: 6, and an HVR-L3 having the amino acid of SEQ ID NO: 7; and a heavy chain variable domain comprising an HVR-H1 having the amino acid sequence of SEQ ID NO: 9, an HVR-H2 having the amino acid of SEQ ID NO: 10, and an HVR-H3 having the amino acid of SEQ ID NO: 11.
2. The use of claim 1, wherein the inherited retinal disease is retinitis pigmentosa (RP), choroideremia, Stargardt disease, cone-rod dystrophy, leber congenital amaurosis, X-linked RP, or Usher Syndrome.
3. Use of an anti-C1q antibody or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of retinal detachment in a human patient, wherein the medicament is for intravitreal injection at a dose of about 1 mg to about 10 mg of the anti-C1q antibody or an antigen-binding fragment thereof, and
wherein the anti-C1q antibody or an antigen-binding fragment thereof comprises a light chain variable domain comprising an HVR-L1 having the amino acid sequence of SEQ ID NO: 5, an HVR-L2 having the amino acid of SEQ ID NO: 6, and an HVR-L3 having the amino acid of SEQ ID NO: 7; and a heavy chain variable domain comprising an HVR-H1 having the amino acid sequence of SEQ ID NO: 9, an HVR-H2 having the amino acid of SEQ ID NO: 10, and an HVR-H3 having the amino acid of SEQ ID NO: 11.
4. The use of claim 3, wherein the anti-C1q antibody or an antigen-binding fragment thereof is to be administered before retinal detachment surgery, after retinal detachment surgery, or simultaneous with retinal detachment surgery.
5. The use of any one of claims 1-4, wherein the use restores vision in the human patient, or improves vision in the human patient.

6. The use of any one of claims 1-5, wherein the anti-C1q antibody or an antigen-binding fragment thereof comprises a light chain variable domain comprising an amino acid sequence with at least about 95% homology to the amino acid sequence selected from SEQ ID NO: 4 and 35-38 and wherein the light chain variable domain comprises an HVR-L1 having the amino acid sequence of SEQ ID NO: 5, an HVR-L2 having the amino acid of SEQ ID NO: 6, and an HVR-L3 having the amino acid of SEQ ID NO: 7.
7. The use of claim 6, wherein the light chain variable domain comprises an amino acid sequence selected from SEQ ID NO: 4 and 35-38.
8. The use of any one of claims 1-7, wherein the anti-C1q antibody or an antigen-binding fragment thereof comprises a heavy chain variable domain comprising an amino acid sequence with at least about 95% homology to the amino acid sequence selected from SEQ ID NO: 8 and 31-34 and wherein the heavy chain variable domain comprises an HVR-H1 having the amino acid sequence of SEQ ID NO: 9, an HVR-H2 having the amino acid of SEQ ID NO: 10, and an HVR-H3 having the amino acid of SEQ ID NO: 11.
9. The use of claim 8, wherein the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NO: 8 and 31-34.
10. The use of any one of claims 1-9, wherein the anti-C1q antibody or an antigen-binding fragment thereof is a monoclonal antibody, a humanized antibody, a human antibody, a chimeric antibody, or antibody derivative thereof.
11. The use of any one of claims 1-10, wherein the antigen binding fragment is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, a Fv fragment, a diabody, or a single chain antibody molecule.
12. The use of claim 11, wherein the Fab fragment comprises a heavy chain Fab fragment of SEQ ID NO: 39 and a light chain Fab fragment of SEQ ID NO: 40.
13. The use of any one of claims 1-12, wherein the anti-C1q antibody or an antigen-binding fragment thereof is to be administered once a week, once every other week, once every three weeks, once a month, once every four weeks, once every six weeks, once every 8 weeks, once every other month, once every 10 weeks, once every 12 weeks, once every three months, or once every 4 months.

14. The use of claim 13, wherein the anti-C1q antibody or an antigen-binding fragment thereof is to be administered for at least 3 months, at least 4 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, or at least 12 months.
15. The use of claim 13 or 14, wherein the anti-C1q antibody or an antigen-binding fragment thereof is to be administered for 12 months.
16. The use of any one of claims 1-15, wherein the dose comprises about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, or about 10 mg of the anti-C1q antibody or an antigen-binding fragment thereof.
17. The use of any one of claims 1-16, wherein the dose comprises about 1 mg of the anti-C1q antibody or an antigen-binding fragment thereof.
18. The use of any one of claims 1-16, wherein the dose comprises about 2.5 mg of the anti-C1q antibody or an antigen-binding fragment thereof.
19. The use of any one of claims 1-16, wherein the dose comprises about 5 mg of the anti-C1q antibody or an antigen-binding fragment thereof.
20. The use of any one of claims 1-16, wherein the dose comprises about 2 mg of the anti-C1q antibody or an antigen-binding fragment thereof.
21. The use of any one of claims 1-16, wherein the dose comprises about 7.5 mg of the anti-C1q antibody or an antigen-binding fragment thereof.
22. The use of any one of claims 1-16, wherein the dose comprises about 10 mg of the anti-C1q antibody or an antigen-binding fragment thereof.
23. The use of any one of claims 1-16, wherein the dose comprises about 1 mg to about 2.5 mg, about 2.5 mg to about 5 mg, about 5 mg to about 7.5 mg, or about 7.5 mg to about 10 mg of the anti-C1q antibody or an antigen-binding fragment thereof.